Van Lanschot Kempen Investment Management N.V. Purchases 77,923 Shares of Bristol-Myers Squibb (NYSE:BMY)

Van Lanschot Kempen Investment Management N.V. increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 13,229.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 78,512 shares of the biopharmaceutical company's stock after purchasing an additional 77,923 shares during the quarter. Van Lanschot Kempen Investment Management N.V.'s holdings in Bristol-Myers Squibb were worth $4,441,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Morse Asset Management Inc grew its holdings in shares of Bristol-Myers Squibb by 25.0% in the third quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock worth $517,000 after acquiring an additional 2,000 shares during the period. Tudor Financial Inc. bought a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at about $250,000. Pine Valley Investments Ltd Liability Co increased its position in shares of Bristol-Myers Squibb by 1.3% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company's stock valued at $2,323,000 after purchasing an additional 575 shares during the last quarter. World Investment Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 18.7% in the 3rd quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock worth $2,282,000 after purchasing an additional 6,954 shares during the period. Finally, Arvest Bank Trust Division bought a new stake in Bristol-Myers Squibb during the third quarter valued at approximately $1,724,000. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of the company's stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BMY has been the subject of a number of recent research reports. Truist Financial boosted their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Jefferies Financial Group cut their price objective on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday. UBS Group decreased their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY traded down $0.83 during mid-day trading on Friday, hitting $47.86. 16,292,011 shares of the company's stock traded hands, compared to its average volume of 12,961,714. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company's 50-day moving average is $56.37 and its two-hundred day moving average is $56.47. The company has a market capitalization of $97.38 billion, a P/E ratio of -10.83, a PEG ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.25. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same period last year, the company earned ($4.40) EPS. On average, equities analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.18%. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.